Lightchain Capital

Recent News

wugen-logo-400
December 11, 2022

Wugen Presents Data Supporting Clinical Development of WU-NK-101 for Relapsed / Refractory AML at the American Society of Hematology’s (ASH) 64th Annual Meeting

READ MORE
NextRNA-Logo-FullColor-400
December 08, 2022

NextRNA Therapeutics to Participate in Upcoming 5th Annual RNA-Targeted Drug Discovery Summit

READ MORE
CareVet-Logo-New
November 29, 2022

CareVet Celebrates One Year of The Ultimate CarePackage

READ MORE
Logo-Geneoscopy-400
November 28, 2022

Colorectal Cancer: Screening Options and Potential Emerging Role for Pharmacists

READ MORE
Logo-Geneoscopy-400
November 28, 2022

Colorectal Cancer: Screening Options and Potential Emerging Role for Pharmacists

READ MORE
wugen-logo-400
November 10, 2022

Wugen to Present at the Upcoming Jefferies London Healthcare Conference

READ MORE
wugen-logo-400
November 07, 2022

Wugen to Present Data Characterizing WU-NK-101 at The Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting

READ MORE
wugen-logo-400
November 03, 2022

Wugen to Present Data on WU-NK-101 for Relapsed / Refractory Acute Myelogenous Leukemia at The American Society of Hematology’s (ASH) 64th Annual Meeting

READ MORE
C4-logo-400
November 03, 2022

C4 Therapeutics Reports Third Quarter 2022 Financial Results and Recent Business Highlights

READ MORE

Contact Us

Lightchain Capital, LLC
PO Box 31729
St. Louis, MO 63131

 

LinkedIn

Submit

©2024 LIGHTCHAIN CAPITAL, LLC  All Rights Reserved | Privacy Policy
Website by Tidal Media Group